Detalhe da pesquisa
1.
Interleukin-31 and soluble CD40L: new candidate serum biomarkers that predict therapeutic response in multiple sclerosis.
Neurol Sci
; 43(11): 6271-6278, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35849199
2.
Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis.
Heliyon
; 7(6): e07263, 2021 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-34179535